We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
London-based Epsilogen has been awarded a £1m grant from the UK’s innovation agency Innovate UK to further develop a novel immunoglobulin E (IgE) antibody to treat cancer.